BIO vs GKOS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 04, 2026

BIO

57.4
AI Score
VS
BIO Wins

GKOS

34.3
AI Score

Investment Advisor Scores

BIO

57score
Recommendation
HOLD

GKOS

34score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric BIO GKOS Winner
Forward P/E 40.6504 1666.6667 BIO
PEG Ratio 1.1905 1.64 BIO
Revenue Growth -0.1% 58.0% GKOS
Earnings Growth 18.7% 1896.3% GKOS
Tradestie Score 57.4/100 34.3/100 BIO
Profit Margin 8.6% -24.6% BIO
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY BIO

Relative Price Performance (Last 90 Days)

BIO 1M: +6.1% · 3M: +6.7% GKOS 1M: +40.6% · 3M: +26.6%

Current Technical Phase

BIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 58

RSI (14): 58.2 · Price: $386.48

GKOS

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (4.6% over 20 days), RSI 66

RSI (14): 66.4 · Price: $236.19

Fundamentals Snapshot

Metric BIO GKOS
Market Cap — —
Forward P/E 39.0 168.7
Trailing P/E 10.3 —
Revenue (TTM) — —
Revenue Growth 0.0% 0.6%
Gross Margin 0.5% 0.8%
Operating Margin 0.1% 0.0%
EPS 37.64 -2.95
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.